Qiu Miaozhen, Zhou Yixin, Zhang Xinke, Wang Zixian, Wang Fang, Shao Jianyong, Lu Jiabin, Jin Ying, Wei Xiaoli, Zhang Dongsheng, Wang Fenghua, Li Yuhong, Yang Dajun, Xu Ruihua
Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng Road East, Guangzhou 510060, China.
BMC Cancer. 2014 Nov 7;14:823. doi: 10.1186/1471-2407-14-823.
Lauren-classification and human epidermal growth factor receptor 2 (HER2) status are two important pathological features of gastric cancer patients. The prognostic value of HER2 in gastric cancer remains controversial. Intestinal type gastric cancer has better prognosis and higher HER2 positive proportion. What is the interaction between these two factors? We hypothesized that a combination of Lauren-classification and human epidermal growth factor receptor 2 (HER2) status (L-H status) might be more meaningful than either factor alone.
We collected 838 gastric cancer patients at all stages who had received treatment in our cancer center. This study was registered in the website of ClinicalTrials.Gov, with the number NCT01927146. We divided the patients into six groups according to their L-H status: Group A, HER2 negative and intestinal type; Group B, HER2 positive and intestinal type; Group C, HER2 negative and diffuse type; Group D, HER2 positive and diffuse type; Group E, HER2 negative and mixed type; and Group F, HER2 positive and mixed type.
Diffuse type and intestinal type accounted for 51.0% and 33.9%, respectively. The proportion of HER2 positive patients was 11.2%, 25.4%, 2.1% and 10.2% in the whole patient group, intestinal, diffuse and mixed type, respectively. Median overall survival was 34.0 months, 25.3 months, 27.6 months, 19.2 months, 25.9 months and 26.4 months in the six groups patients, P = 0.053. There was a significant difference in survival among the first four groups (P < 0.001). HER2 was an independent prognostic factor in the intestinal type and in stage I + II patients, but not in the diffuse type or stage III + IV patients. L-H status was an independent prognostic factor in patients at all stages. For the diffuse and intestinal types, the multivariate analysis showed that HER2 was not an independent prognostic factor, while Lauren classification and L-H status were. Moreover, L-H status was a better prognostic factor than the Lauren classification.
L-H status is a prognostic factor in diffuse and intestinal type patients, but not in the mixed type. Patients with HER2 negative and intestinal type had the best survival, while patients with HER2 positive status and diffuse type had the worst survival.
劳伦分类法和人表皮生长因子受体2(HER2)状态是胃癌患者的两个重要病理特征。HER2在胃癌中的预后价值仍存在争议。肠型胃癌预后较好且HER2阳性比例较高。这两个因素之间有什么相互作用?我们假设劳伦分类法与人表皮生长因子受体2(HER2)状态(L-H状态)的组合可能比单独的任何一个因素更有意义。
我们收集了在我们癌症中心接受治疗的838例各阶段胃癌患者。本研究已在ClinicalTrials.Gov网站注册,注册号为NCT01927146。我们根据患者的L-H状态将其分为六组:A组,HER2阴性且为肠型;B组,HER2阳性且为肠型;C组,HER2阴性且为弥漫型;D组,HER2阳性且为弥漫型;E组,HER2阴性且为混合型;F组,HER2阳性且为混合型。
弥漫型和肠型分别占51.0%和33.9%。HER2阳性患者在全组、肠型、弥漫型和混合型中的比例分别为11.2%、25.4%、2.1%和10.2%。六组患者的中位总生存期分别为34.0个月、25.3个月、27.6个月、19.2个月、25.9个月和26.4个月,P = 0.053。前四组患者的生存期存在显著差异(P < 0.001)。HER2是肠型和I + II期患者的独立预后因素,但不是弥漫型或III + IV期患者的独立预后因素。L-H状态是所有阶段患者的独立预后因素。对于弥漫型和肠型,多因素分析显示HER2不是独立预后因素,而劳伦分类法和L-H状态是独立预后因素。此外,L-H状态是比劳伦分类法更好的预后因素。
L-H状态是弥漫型和肠型患者的预后因素,但不是混合型患者的预后因素。HER2阴性且为肠型的患者生存期最佳,而HER2阳性且为弥漫型的患者生存期最差。